StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) operating KPIs

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)

Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –

BeOne Medicines aBRAXANE (nab-paclitaxel — BMS/Celgene China Partnered) ($M, FY18–FY21) ($M)

Form 10-Q / 10-K Segment Disaggregation Note (XBRL)

Latest, Q4 2021
0
Period ended Dec 31, 2021
Change on a year earlier
-100.0%
0.40 in Q4 2020
History
12 quarters
Since Q1 2019
Sources
7
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedABRAXANE (nab-paclitaxel — BMS/Celgene China Partnered) ($M, FY18–FY21) ($M)Year on yearSource
Q4 2021Dec 31, 20210-100.0%Form 10-K (filed 2022-02-28) ↗
Q3 2021Sep 30, 20210–Form 10-Q (filed 2021-11-04) ↗
Q2 2021Jun 30, 20210-100.0%Form 10-Q (filed 2021-08-05) ↗
Q1 2021Mar 31, 20210-100.0%Form 10-Q (filed 2021-05-06) ↗
Q4 2020Dec 31, 20200.40-98.5%Form 10-K (filed 2022-02-28) ↗
Q3 2020Sep 30, 20200-100.0%Form 10-Q (filed 2021-11-04) ↗
Q2 2020Jun 30, 20200.20-99.4%Form 10-Q (filed 2021-08-05) ↗
Q1 2020Mar 31, 202017.1-36.9%Form 10-Q (filed 2021-05-06) ↗
Q4 2019Dec 31, 201926.9–Form 10-K (filed 2022-02-28) ↗
Q3 2019Sep 30, 201922.5–Form 10-Q (filed 2020-11-05) ↗
Q2 2019Jun 30, 201934.7–Form 10-Q (filed 2020-08-06) ↗
Q1 2019Mar 31, 201927.1–Form 10-Q (filed 2020-05-11) ↗

Cite this data

StockData. (2026). BeOne Medicines ABRAXANE (nab-paclitaxel — BMS/Celgene China Partnered) ($M, FY18–FY21) ($M), quarterly Q1 2019–Q4 2021 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_abraxane

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.